332 related articles for article (PubMed ID: 25808018)
21. Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy.
Byrne CJ; Parton T; McWhinney B; Fennell JP; O'Byrne P; Deasy E; Egan S; Enright H; Desmond R; Ryder SA; D'Arcy DM; McHugh J; Roberts JA
J Antimicrob Chemother; 2018 Apr; 73(4):995-1003. PubMed ID: 29272419
[TBL] [Abstract][Full Text] [Related]
22. Ceftriaxone dosing in patients admitted from the emergency department with sepsis.
Heffernan AJ; Curran RA; Denny KJ; Sime FB; Stanford CL; McWhinney B; Ungerer J; Roberts JA; Lipman J
Eur J Clin Pharmacol; 2021 Feb; 77(2):207-214. PubMed ID: 32974748
[TBL] [Abstract][Full Text] [Related]
23. Teicoplanin binding in plasma following administration of increasing intravenous doses to healthy volunteers.
Bernareggi A; Borgonovi M; Del Favero A; Rosina R; Gavanaghi L
Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():256-60. PubMed ID: 1840325
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis.
Brink AJ; Richards GA; Schillack V; Kiem S; Schentag J
Int J Antimicrob Agents; 2009 May; 33(5):432-6. PubMed ID: 19091521
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.
Sturm AW; Allen N; Rafferty KD; Fish DN; Toschlog E; Newell M; Waibel B
Pharmacotherapy; 2014 Jan; 34(1):28-35. PubMed ID: 23864417
[TBL] [Abstract][Full Text] [Related]
26. Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration.
Burkhardt O; Kumar V; Katterwe D; Majcher-Peszynska J; Drewelow B; Derendorf H; Welte T
J Antimicrob Chemother; 2007 Feb; 59(2):277-84. PubMed ID: 17185298
[TBL] [Abstract][Full Text] [Related]
27. Factors impacting unbound vancomycin concentrations in different patient populations.
Oyaert M; Spriet I; Allegaert K; Smits A; Vanstraelen K; Peersman N; Wauters J; Verhaegen J; Vermeersch P; Pauwels S
Antimicrob Agents Chemother; 2015 Nov; 59(11):7073-9. PubMed ID: 26349820
[TBL] [Abstract][Full Text] [Related]
28. Multicenter Population Pharmacokinetic Study of Unbound Ceftriaxone in Critically Ill Patients.
Heffernan AJ; Sime FB; Kumta N; Wallis SC; McWhinney B; Ungerer J; Wong G; Joynt GM; Lipman J; Roberts JA
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0218921. PubMed ID: 35575578
[TBL] [Abstract][Full Text] [Related]
29. Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumonia.
Dreesen E; Gijsen M; Elkayal O; Annaert P; Debaveye Y; Wauters J; Karlsson MO; Spriet I
J Antimicrob Chemother; 2022 Aug; 77(9):2479-2488. PubMed ID: 35815604
[TBL] [Abstract][Full Text] [Related]
30. Validating a novel three-times-weekly post-hemodialysis ceftriaxone regimen in infected Indigenous Australian patients-a population pharmacokinetic study.
Tsai D; Zam BB; Tongs C; Chiong F; Sajiv C; Pawar B; Ashok A; Cooper BP; Tong SYC; Janson S; Wallis SC; Roberts JA; Parker SL
J Antimicrob Chemother; 2023 Aug; 78(8):1963-1973. PubMed ID: 37367723
[TBL] [Abstract][Full Text] [Related]
31. Population pharmacokinetic/pharmacodynamic target attainment of ceftriaxone 2 g once daily in non-critically ill hospitalized adult patients during the acute phase of infection.
van den Broek AK; van Schip A; Visser CE; Bos JC; Prins JM; van Hest RM
Br J Clin Pharmacol; 2023 Nov; 89(11):3262-3272. PubMed ID: 37309251
[TBL] [Abstract][Full Text] [Related]
32. Changes in ceftriaxone pharmacokinetics/pharmacodynamics during the early phase of sepsis: a prospective, experimental study in the rat.
Selmi V; Loriga B; Vitali L; Carlucci M; Di Filippo A; Carta G; Sgambati E; Tofani L; De Gaudio AR; Novelli A; Adembri C
J Transl Med; 2016 Nov; 14(1):316. PubMed ID: 27846855
[TBL] [Abstract][Full Text] [Related]
33. Ceftriaxone pharmacokinetic properties during continuous veno-veno haemofiltration using an in vitro adult, paediatric and neonatal model.
Harvey B; Johnson TN; Yeomanson D; Mulla H; Mayer AP
Perfusion; 2014 Jan; 29(1):32-8. PubMed ID: 23863489
[TBL] [Abstract][Full Text] [Related]
34. Ceftriaxone pharmacokinetics during iatrogenic hydroxyethyl starch-induced hypoalbuminemia: a model to explore the effects of decreased protein binding capacity on highly bound drugs.
Mimoz O; Soreda S; Padoin C; Tod M; Petitjean O; Benhamou D
Anesthesiology; 2000 Sep; 93(3):735-43. PubMed ID: 10969307
[TBL] [Abstract][Full Text] [Related]
35. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics.
Ulldemolins M; Roberts JA; Wallis SC; Rello J; Lipman J
J Antimicrob Chemother; 2010 Aug; 65(8):1771-8. PubMed ID: 20530507
[TBL] [Abstract][Full Text] [Related]
36. Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration.
Wenisch JM; Meyer B; Fuhrmann V; Saria K; Zuba C; Dittrich P; Thalhammer F
J Antimicrob Chemother; 2012 Apr; 67(4):977-83. PubMed ID: 22210754
[TBL] [Abstract][Full Text] [Related]
37. [Pharmacokinetics of ceftriaxone in intensive care].
Bouget J; Garré M; Reyman JM; Guedes Y; Cartier F
Pathol Biol (Paris); 1988 Jun; 36(5 Pt 2):706-10. PubMed ID: 3054752
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis.
Burkhardt O; Hafer C; Langhoff A; Kaever V; Kumar V; Welte T; Haller H; Fliser D; Kielstein JT
Nephrol Dial Transplant; 2009 Jan; 24(1):267-71. PubMed ID: 18723863
[TBL] [Abstract][Full Text] [Related]
39. Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients.
Sime FB; Byrne CJ; Parker S; Stuart J; Butler J; Starr T; Pandey S; Wallis SC; Lipman J; Roberts JA
Crit Care; 2019 Jun; 23(1):205. PubMed ID: 31171022
[TBL] [Abstract][Full Text] [Related]
40. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study.
Roberts JA; Boots R; Rickard CM; Thomas P; Quinn J; Roberts DM; Richards B; Lipman J
J Antimicrob Chemother; 2007 Feb; 59(2):285-91. PubMed ID: 17135183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
